The Emphysema market, estimated to be valued at USD 5.36 Billion in 2025, is projected to exhibit a steady CAGR of 4.0%, reaching USD 7.05 Billion by 2032. Growth is fueled by the rising prevalence of chronic obstructive pulmonary disease (COPD), increased exposure to air pollutants and tobacco smoke, and a growing aging population vulnerable to respiratory ailments. Technological advancements in diagnostic imaging, the development of minimally invasive lung volume reduction techniques, and the introduction of novel bronchodilator therapies are significantly enhancing disease management. Moreover, expanding public health initiatives, early screening programs, and increased R&D investments into regenerative and gene therapies are expected to bolster the market growth across key global markets.
Market Takeaways
Emphysema Market Report Coverage
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/emphysema-market
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 5.36 Billion |
|
Estimated Value by 2032 |
USD 7.05 Billion |
|
Growth Rate |
Poised to exhibit a CAGR of 4.0% |
|
Historical Data |
2020-2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Trends |
|
|
Opportunities |
|
|
Restraints & Challenges |
|
Market Dynamics
The Emphysema market is experiencing steady growth, driven by the increasing global burden of chronic obstructive pulmonary disease (COPD), rising geriatric population, and heightened exposure to risk factors such as air pollution and tobacco smoke. Growing awareness of the importance of early diagnosis and lung health management is fostering greater demand for advanced therapeutic interventions, including long-acting bronchodilators, inhaled corticosteroids, and supplemental oxygen therapy.
Advancements in non-invasive imaging technologies, pulmonary function testing, and the development of targeted drug delivery systems are improving diagnostic precision and therapeutic efficacy. Additionally, innovations in minimally invasive procedures—such as endobronchial valve placement and bronchoscopic lung volume reduction—are expanding treatment options for patients with severe emphysema unresponsive to conventional pharmacotherapy.
Healthcare providers are increasingly emphasizing integrated care approaches, which combine pharmacological treatments with pulmonary rehabilitation and smoking cessation programs to improve long-term outcomes. Market players are also investing in novel drug development, including regenerative and gene therapies aimed at reversing alveolar damage and restoring lung function.
In November 2022, Pulmonx Corporation, a global leader in minimally invasive treatments for severe lung disease, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) had approved Zephyr Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by the Pharmaceuticals and Medical Devices Agency (PMDA). Zephyr Valve is a minimally invasive treatment option that can deliver significant benefits to patients, including improvements in lung function, exercise capacity, and quality of life.
Market Trends
The integration of artificial intelligence into pulmonary imaging is emerging as a transformative advancement in emphysema diagnosis and management. In June 2025, Olympus launched its SeleCT AI screening platform, powered by 4DMedical, which automatically analyzes existing chest CT scans to identify candidates for bronchoscopic lung volume reduction (BLVR). The system flags patients with severe emphysema suitable for interventions such as the Spiration Valve System, alerting physicians and facilitating earlier treatment access. This AI-enabled approach is being increasingly adopted across healthcare systems in North America and Europe, enhancing diagnostic accuracy, reducing delays, and enabling more personalized therapy planning. The trend reflects a broader shift toward precision diagnostics and minimally invasive respiratory care.
Dual-mechanism bronchodilators are gaining traction as an advanced treatment option for moderate-to-severe emphysema. The FDA approval of ensifentrine (Ohtuvayre) in June 2024 marked the entry of the first inhaled therapy that combines PDE3 and PDE4 inhibition, offering both bronchodilatory and anti-inflammatory effects. Clinical trials demonstrated that ensifentrine significantly improved lung function and reduced exacerbation rates, outperforming conventional monotherapy bronchodilators. With a favorable safety profile and convenient once-daily inhalation, this novel dual-action therapy is quickly becoming a preferred option among pulmonologists seeking to optimize outcomes in patients with persistent airflow limitation. The approval of Ohtuvayre signals a growing shift toward multi-functional inhaled therapies that target both symptom control and underlying inflammation in chronic respiratory diseases like emphysema.
Market Opportunities
The emergence of home-based pulmonary rehabilitation programs and telehealth platforms is creating a significant opportunity to extend emphysema management beyond traditional clinical environments. Devices like PulmoBell, a sensor-based respiratory assistive tool, are being developed to support continuous breathing exercises and activity monitoring in COPD/emphysema patients from the comfort of their homes. This digital approach helps sustain pulmonary function improvements gained through in-person therapy and promotes long-term engagement.
As adoption grows across underserved and remote regions, these solutions are positioned to enhance patient adherence, reduce hospital readmissions, and alleviate the burden on overextended healthcare systems. The integration of tele-rehabilitation into routine care models represents a scalable and cost-effective strategy to improve disease outcomes across geographies.
The growing adoption of IoT-enabled smart inhalers and connected respiratory monitoring systems presents a compelling opportunity to improve adherence and clinical outcomes in emphysema management. These advanced devices enable real-time tracking of medication usage, inhalation technique, and symptom patterns, empowering both patients and clinicians with actionable insights. Recent studies underscore the importance of incorporating robust cybersecurity frameworks and intuitive design to ensure user safety, data integrity, and regulatory compliance. By facilitating personalized treatment adjustments and early intervention, these digital health tools are laying the foundation for data-driven, remote emphysema care, particularly in tech-forward healthcare systems focused on proactive disease management.
In May 2025, a systematic review of qualitative studies published on JMIR Publications revealed that electronic inhaler monitoring devices (EIMDs), also known as smart inhalers, significantly improved medication adherence and inhalation technique in COPD and asthma patients. The findings emphasized that robust usability, patient acceptability, and integration of real-time feedback are key to maximizing clinical impact.
Analyst View
Key Developments
Competitive Landscape
Emphysema Market Segmentation
Regional Insights
Related Reports :